(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.69%) $83.27
(-1.16%) $1.619
(-0.04%) $2 346.20
(-0.15%) $27.50
(0.10%) $923.00
(-0.09%) $0.934
(-0.01%) $11.02
(-0.13%) $0.799
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.74%
@ $9.92
Utstedt: 14 feb 2024 @ 21:58
Avkastning: -33.17%
Forrige signal: feb 13 - 19:33
Forrige signal:
Avkastning: 2.06 %
Live Chart Being Loaded With Signals
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments...
Stats | |
---|---|
Dagens volum | 137 484 |
Gjennomsnittsvolum | 381 566 |
Markedsverdi | 289.76M |
EPS | $0 ( 2024-03-05 ) |
Neste inntjeningsdato | ( $-0.100 ) 2024-05-02 |
Last Dividend | $1.000 ( 2010-01-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -13.00 |
ATR14 | $0.0100 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Zaderej Karen L. | Buy | 84 847 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 975 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 166 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 500 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 086 | Common Stock |
INSIDER POWER |
---|
41.83 |
Last 98 transactions |
Buy: 1 200 055 | Sell: 468 598 |
Volum Korrelasjon
AxoGen Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
EA | 0.869 |
SFET | 0.857 |
CNET | 0.853 |
SMIT | 0.852 |
AHPI | 0.848 |
LLNW | 0.846 |
STAB | 0.845 |
GHVI | 0.839 |
RTPY | 0.838 |
AUID | 0.834 |
10 Mest negative korrelasjoner | |
---|---|
SHYF | -0.915 |
RGLD | -0.91 |
UBFO | -0.902 |
MTRX | -0.899 |
ICUI | -0.897 |
TKNO | -0.893 |
IPKW | -0.892 |
STRA | -0.891 |
VRTS | -0.891 |
SGII | -0.889 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
AxoGen Inc Korrelasjon - Valuta/Råvare
AxoGen Inc Økonomi
Annual | 2023 |
Omsetning: | $159.01M |
Bruttogevinst: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2023 |
Omsetning: | $159.01M |
Bruttogevinst: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2022 |
Omsetning: | $138.58M |
Bruttogevinst: | $114.44M (82.58 %) |
EPS: | $-0.650 |
FY | 2021 |
Omsetning: | $127.36M |
Bruttogevinst: | $104.43M (81.99 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
AxoGen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0417 | 1992-07-10 |
Last Dividend | $1.000 | 2010-01-27 |
Next Dividend | $0 | N/A |
Payout Date | 2010-02-12 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.102 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 1.724 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1992 | $0.0417 | 0.45% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0.0600 | 4.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $1.000 | 24.10% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.134 | 1.500 | -2.69 | -4.03 | [0 - 0.5] |
returnOnAssetsTTM | -0.108 | 1.200 | -3.62 | -4.34 | [0 - 0.3] |
returnOnEquityTTM | -0.220 | 1.500 | -3.56 | -5.33 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.89 | 0.800 | 0.540 | 0.432 | [1 - 3] |
quickRatioTTM | 2.04 | 0.800 | 2.69 | 2.15 | [0.8 - 2.5] |
cashRatioTTM | 1.217 | 1.500 | 4.35 | 6.53 | [0.2 - 2] |
debtRatioTTM | 0.245 | -1.500 | 5.92 | -8.88 | [0 - 0.6] |
interestCoverageTTM | -7.45 | 1.000 | -3.87 | -3.87 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.133 | 2.00 | -0.0443 | -0.0885 | [0 - 30] |
freeCashFlowPerShareTTM | -0.479 | 2.00 | -0.240 | -0.479 | [0 - 20] |
debtEquityRatioTTM | 0.503 | -1.500 | 7.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.804 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.135 | 1.000 | -4.70 | -4.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.119 | 1.000 | -1.771 | -1.771 | [0.2 - 2] |
assetTurnoverTTM | 0.808 | 0.800 | 7.95 | 6.36 | [0.5 - 2] |
Total Score | 1.724 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -13.37 | 1.000 | -1.451 | 0 | [1 - 100] |
returnOnEquityTTM | -0.220 | 2.50 | -2.29 | -5.33 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.479 | 2.00 | -0.160 | -0.479 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.133 | 2.00 | -0.0443 | -0.0885 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.393 | 1.500 | -5.95 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0359 | 1.000 | -3.40 | 0 | [0.1 - 0.5] |
Total Score | -1.990 |
AxoGen Inc
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.